Key Highlights

  • Immuron reported unaudited global FY26 Travelan sales of AUD 7.7 million.
  • FY26 global sales increased 6% from the prior comparative period.
  • Second-half FY26 sales reached AUD 3.5 million, up 7%.
  • The company recorded four consecutive quarters of year-on-year Travelan sales growth.

Immuron Limited (ASX:IMC) reported unaudited global Travelan sales of AUD 7.7 million for FY26, an increase of 6% from the prior comparative period. The update extended a run of four consecutive quarters in which sales exceeded the corresponding period a year earlier.

Second Half Maintains Momentum

Global Travelan sales for the second half of FY26 reached AUD 3.5 million, up 7% year on year. Fourth-quarter sales were AUD 2.0 million, representing a 2% increase. Australian FY26 sales were reported at AUD 5.8 million, making the domestic market an important contributor to the product’s commercial base.

Commercial Sales Sit Alongside the Development Pipeline

Travelan provides Immuron with an existing commercial product while the company continues work on its development portfolio. Recent corporate updates have also included partnering activity around IMM-529, the company’s candidate being developed for Clostridioides difficile infection.

What Could Drive Immuron’s Next Update?

Immuron shares were recently trading at AUD 0.037, giving the company a Market Capitalisation of about AUD 11.95 million. Future attention will be split between continued Travelan sales performance and progress across the development pipeline. Sustaining commercial growth while advancing clinical and partnering milestones would broaden the company’s operating base.